中基健康(000972) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 reached ¥55,136,159.40, an increase of 3.86% compared to the same period last year, and a total revenue of ¥343,059,838.58 for the year-to-date, reflecting a significant growth of 122.52%[4] - Net profit attributable to shareholders for Q3 2023 was ¥4,924,569.94, representing an impressive increase of 88.80%, with a year-to-date net profit of ¥43,011,601.53, up 275.13%[4] - The basic earnings per share for Q3 2023 was ¥0.0064, an increase of 87.79%, while the diluted earnings per share also stood at ¥0.0064, reflecting the same growth rate[4] - Total revenue for Q3 2023 reached CNY 343,059,838.58, a significant increase from CNY 154,169,869.57 in the same period last year, representing a growth of approximately 122.5%[16] - The net profit for Q3 2023 was CNY 43,165,001.80, a significant recovery from a net loss of CNY 24,557,362.28 in the same period last year[17] - Operating profit for the quarter was CNY 43,809,941.54, compared to an operating loss of CNY 24,784,483.78 in Q3 2022[17] - Total revenue from sales of goods and services reached CNY 485,404,622.69, up from CNY 348,581,823.20 in the previous year, indicating a growth of approximately 39.2%[18] Assets and Liabilities - Total assets at the end of Q3 2023 amounted to ¥1,426,861,707.76, marking a 72.88% increase from the previous year[4] - Total assets as of September 30, 2023, were CNY 1,426,861,707.76, compared to CNY 825,364,850.66 at the beginning of the year, marking an increase of approximately 72.9%[15] - Total liabilities reached CNY 1,283,275,612.07, up from CNY 724,943,756.77, indicating a growth of about 77.1%[15] - The total equity attributable to shareholders increased by 45.13% to ¥138,325,788.22 compared to the end of the previous year[4] - The company's equity attributable to shareholders increased to CNY 138,325,788.22 from CNY 95,314,186.69, representing a growth of approximately 45.0%[15] Cash Flow - Cash flow from operating activities showed a negative net amount of ¥-276,157,231.04 year-to-date, indicating a decline of 418.02%[4] - The company reported a net cash outflow from operating activities of CNY -276,157,231.04, contrasting with a net inflow of CNY 86,836,466.34 in the same quarter last year[19] - Cash and cash equivalents as of September 30, 2023, amounted to CNY 219,773,929.20, up from CNY 207,471,741.60 at the beginning of the year[13] - Cash and cash equivalents at the end of the period totaled CNY 219,773,929.20, an increase from CNY 89,271,187.09 at the end of Q3 2022[19] - Total cash inflow from financing activities was CNY 595,000,000.00, with a net cash inflow of CNY 429,825,931.76 after outflows[19] Inventory and Borrowings - The company reported a significant increase in inventory, which reached ¥681,771,219.15, a rise of 214.52% due to increased production output[7] - Inventory increased significantly to CNY 681,771,219.15 from CNY 216,762,597.82, reflecting a growth of about 214.5%[14] - The company experienced a 3203.68% increase in short-term borrowings, totaling ¥396,662,000.00, to support operational needs[7] - Short-term borrowings surged to CNY 396,662,000.00 from CNY 12,006,655.56, reflecting a significant increase[15] Research and Development - Research and development expenses surged to ¥456,285.70, a substantial increase of 633.69% compared to the previous year, highlighting the company's focus on innovation[8] - The company incurred research and development expenses of CNY 456,285.70, compared to CNY 62,190.89 in the same quarter last year, reflecting a substantial increase in investment in innovation[17] Government Support and Expenses - The company received government subsidies amounting to ¥367,019.29 during the reporting period, which contributed to its financial performance[5] - Total operating costs for Q3 2023 were CNY 293,225,200.16, compared to CNY 163,241,345.73 in Q3 2022, indicating an increase of about 79.6%[16] - The company experienced a significant increase in sales expenses, totaling CNY 3,628,371.97, compared to CNY 384,590.15 in the previous year, indicating a strategic push in marketing efforts[17] Audit Status - The company has not undergone an audit for the Q3 report, which may impact investor confidence in the reported figures[20]